{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:23:58Z","timestamp":1748705038210,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bonr.2024.101794","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:45:12Z","timestamp":1721753112000},"page":"101794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Are bone targeted agents still useful in times of immunotherapy? The SAKK 80\/19 BTA pilot study"],"prefix":"10.1016","volume":"22","author":[{"given":"Michael","family":"Mark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso Rojas","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Winder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Petrausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bonr.2024.101794_bb0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1634\/theoncologist.2007-0245","article-title":"Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases","volume":"15","author":"Aapro","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bonr.2024.101794_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00520-010-0868-z","article-title":"Zoledronic acid and atrial fibrillation in cancer patients","volume":"19","author":"Arslan","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.bonr.2024.101794_bb0015","doi-asserted-by":"crossref","first-page":"697298","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.bonr.2024.101794_bb0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00520-011-1230-9","article-title":"Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists","volume":"19","author":"Bouganim","year":"2011","journal-title":"Support. Care Cancer"},{"issue":"8","key":"10.1016\/j.bonr.2024.101794_bb0025","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s00520-016-3154-x","article-title":"Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer","volume":"24","author":"Cleeland","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.bonr.2024.101794_bb0030","first-page":"e168","article-title":"Do physicians follow systemic treatment and funding policy guidelines?","volume":"11","author":"Clemons","year":"2004","journal-title":"Can. J. Clin. Pharmacol."},{"issue":"8 Suppl","key":"10.1016\/j.bonr.2024.101794_bb0035","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bonr.2024.101794_bb0040","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Gillessen, S., et al., Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)\u2014SAKK 96\/12 (REDUSE). Journal of Clinical Oncology, 2019. 37(7_suppl): p. 139\u2013139.","key":"10.1016\/j.bonr.2024.101794_bb0045","DOI":"10.1200\/JCO.2019.37.7_suppl.139"},{"issue":"5","key":"10.1016\/j.bonr.2024.101794_bb0050","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1634\/theoncologist.2007-0200","article-title":"Use of intravenous bisphosphonates in older women with breast cancer","volume":"13","author":"Giordano","year":"2008","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.bonr.2024.101794_bb0055","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.bonr.2024.101794_bb0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clinthera.2010.03.014","article-title":"Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis","volume":"32","author":"John Camm","year":"2010","journal-title":"Clin. Ther."},{"issue":"6717","key":"10.1016\/j.bonr.2024.101794_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bonr.2024.101794_bb0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12885-018-4412-8","article-title":"PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"issue":"28","key":"10.1016\/j.bonr.2024.101794_bb0075","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2024.101794_bb0080","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/j.0022-0337.2008.72.8.tb04568.x","article-title":"Bisphosphonates and osteonecrosis of the jaws","volume":"72","author":"Mariotti","year":"2008","journal-title":"J. Dent. Educ."},{"key":"10.1016\/j.bonr.2024.101794_bb0085","doi-asserted-by":"crossref","first-page":"100273","DOI":"10.1016\/j.jbo.2019.100273","article-title":"Patterns of care for patients with metastatic bone disease in solid tumors: a cross-sectional study from Switzerland (SAKK 95\/16)","volume":"21","author":"Mark","year":"2020","journal-title":"J Bone Oncol"},{"issue":"12","key":"10.1016\/j.bonr.2024.101794_bb0090","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2024.101794_bb0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s12094-018-02023-5","article-title":"The RANK-RANKL axis: an opportunity for drug repurposing in cancer?","volume":"21","author":"Peters","year":"2019","journal-title":"Clin. Transl. Oncol."},{"issue":"10","key":"10.1016\/j.bonr.2024.101794_bb0100","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"Peters","year":"2020","journal-title":"J. Thorac. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Planchard, D., et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>&#x2020;<\/sup>. Annals of Oncology, 2018. 29: p. iv192-iv237.","key":"10.1016\/j.bonr.2024.101794_bb0105","DOI":"10.1093\/annonc\/mdy275"},{"issue":"12","key":"10.1016\/j.bonr.2024.101794_bb0110","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.bonr.2024.101794_bb0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bonr.2024.101794_bb0120","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bonr.2024.101794_bb0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bonr.2024.101794_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2018.10.011","article-title":"RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment","volume":"133","author":"van Dam","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.bonr.2024.101794_bb0135","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00520-015-2908-1","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"von Moos","year":"2016","journal-title":"Support. Care Cancer"},{"doi-asserted-by":"crossref","unstructured":"von Moos, R., et al., Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96\/12 (REDUSE). Annals of Oncology, 2018. 29: p. viii609-viii610.","key":"10.1016\/j.bonr.2024.101794_bb0140","DOI":"10.1093\/annonc\/mdy300.020"},{"key":"10.1016\/j.bonr.2024.101794_bb0145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"33","key":"10.1016\/j.bonr.2024.101794_bb0150","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1200\/JCO.2010.28.7524","article-title":"Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer","volume":"28","author":"Wilkinson","year":"2010","journal-title":"J. Clin. Oncol."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187224000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187224000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T06:09:34Z","timestamp":1728454174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187224000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"alternative-id":["S2352187224000615"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2024.101794","relation":{},"ISSN":["2352-1872"],"issn-type":[{"type":"print","value":"2352-1872"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are bone targeted agents still useful in times of immunotherapy? The SAKK 80\/19 BTA pilot study","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2024.101794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101794"}}